Abstract:We have previously developed an rAAV2/HBoV1 vector in which a recombinant adeno-associated virus 2 (rAAV2) genome is pseudopackaged into a human bocavirus 1 (HBoV1) capsid. Recently, the production of rAAV2/HBoV1 in human embryonic kidney (HEK) 293 cells has been greatly improved in the absence of any HBoV1 nonstructural proteins (NS). This NS-free production system yields over 16-fold more vectors than the original production system that necessitates NS expression. The production of rAAV with infection of baculovirus expression vector (BEV) in the suspension culture of Sf9 insect cells is highly efficient and scalable. Since the replication of the rAAV2 genome in the BEV system is well established, we aimed to develop a BEV system to produce the rAAV2/HBoV1 vector in Sf9 cells. We optimized the usage of translation initiation signals of the HBoV1 capsid proteins (Cap), and constructed a BEV Bac-AAV2Rep-HBoV1Cap, which expresses the AAV2 Rep78 and Rep52 as well as the HBoV1 VP1, VP2, and VP3 at the appropriate ratios. We found that it is sufficient as a trans helper to the production of rAAV2/HBoV1 in Sf9 cells that were co-infected with the transfer Bac-AAV2ITR-GFP-luc that carried a 5.4-kb oversized rAAV2 genome with dual reporters. Further study found that incorporation of an HBoV1 small NS, NP1, in the system maximized the viral DNA replication and thus the rAAV2/HBoV1 vector production at a level similar to that of the rAAV2 vector in Sf9 cells. However, the transduction potency of the rAAV2/HBoV1 vector produced from BEV-infected Sf9 cells was 5–7-fold lower in polarized human airway epithelia than that packaged in HEK293 cells. Transmission electron microscopy analysis found that the vector produced in Sf9 cells had a high percentage of empty capsids, suggesting the pseudopackage of the rAAV2 genome in HBoV1 capsid is not as efficient as in the capsids of AAV2. Nevertheless, our study demonstrated that the rAAV2/HBoV1 can be produced in insect cells with BEVs at a comparable yield to rAAV, and that the highly efficient expression of the HBoV1 capsid proteins warrants further optimization.

Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture

Advanced biomanufacturing and evaluation of adeno-associated virus

[Large-Scale Production of Recombinant Adeno-Associated Virus (Raav)].

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

Process Improvement of Adeno-Associated Virus Production

Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells

Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platforms

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Transcriptome analysis of Sf9 insect cells during production of recombinant Adeno‐associated virus

Construction of an rAAV Producer Cell Line through Synthetic Biology

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells.

Towards a scalable bioprocess for rAAV production using a HeLa stable cell line

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.